Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics Inc (VYGR) is a leader in developing gene therapies for central nervous system disorders through its proprietary TRACER™ platform. This page provides investors and researchers with essential updates on clinical developments, strategic partnerships, and scientific breakthroughs in AAV-based treatments.
Access curated press releases and news articles covering key milestones in Voyager’s pipeline, including therapies for Parkinson’s disease, ALS, and Friedreich’s ataxia. Stay informed about advancements in blood-brain barrier penetration technology and preclinical validation studies across multiple species.
Our repository features updates on clinical trial progress, regulatory developments, and collaborative research initiatives. Discover analysis of vector optimization achievements and manufacturing scalability efforts critical to gene therapy commercialization.
Bookmark this page for consolidated access to verified information about Voyager’s neurogenetic innovations. Check regularly for objective reporting on therapeutic candidate progression and industry leadership in CNS-targeted gene delivery solutions.
Voyager Therapeutics (NASDAQ: VYGR) presented new preclinical data on a vectorized anti-tau antibody at the 24th Annual Meeting of the American Society of Gene and Cell Therapy. The data indicates durable expression within the central nervous system, which may provide a novel single-dose strategy for treating tauopathies like Alzheimer's. Key findings include a 59% reduction in tau pathology after intravenous administration in rodent models and lasting expression for at least 28 days. A virtual investor event is planned for July 2021 to discuss further developments.
Voyager Therapeutics (NASDAQ: VYGR) presented preclinical data at the 24th Annual Meeting of the American Society of Gene and Cell Therapy, showing significant advancements in gene therapy for neurological diseases. Their novel AAV capsids demonstrated up to 1000-fold higher transgene expression in the brain compared to traditional AAV therapy after intravenous administration. The lead candidate, TRACER 9P801, exhibited a favorable tolerability profile with no observed toxicity. This breakthrough underscores the potential for treating CNS disorders with lower doses than current AAV serotypes.
Voyager Therapeutics (VYGR) reported Q1 2021 financial results, highlighting progress in its Huntington's disease program, VY-HTT01. The FDA cleared its IND application, with plans to initiate a Phase 1/2 trial by Q4 2021. The company also developed novel AAV capsids that improve gene delivery. However, collaboration revenues dropped to $6.5 million from $18.1 million a year prior, with a net loss of $21.6 million. The company has $153.1 million in cash as of March 31, 2021, positioning itself for upcoming trials and innovations.
Voyager Therapeutics (Nasdaq: VYGR) announced significant data presentations at the ASGCT 24th Annual Meeting, scheduled for May 11-14, 2021. Key highlights include:
- First reporting on novel capsid technology.
- Oral presentations on RNA-driven AAV capsid evolution, anti-Tau antibody efficacy in mouse models, and capsid separation techniques.
- Poster presentations on AAV gene therapy for chronic pain and AAV vector ultrafiltration.
- Industry symposium on advancing AAV gene therapy for CNS diseases.
For more information, visit Voyager's website.
Voyager Therapeutics (Nasdaq: VYGR) announced the FDA has lifted the clinical hold on its IND application for VY-HTT01, a gene therapy for Huntington’s disease. The therapy aims to reduce the expression of the huntingtin gene to alter disease progression. The Phase 1/2 clinical trial, named VYTAL, will evaluate the safety and tolerability of VY-HTT01 in early-stage HD patients. This trial is a crucial step as there are currently no approved disease-modifying therapies for HD, which affects over 30,000 individuals in the U.S. with debilitating symptoms.
Voyager Therapeutics (NASDAQ: VYGR) has made significant progress in its lead program, VY-HTT01, for Huntington's disease, aiming to respond to FDA requests regarding its Investigational New Drug (IND) application by mid-2021. The company reported a fourth quarter 2020 net loss of $15.9 million, with total collaboration revenues of $6.5 million for the quarter, down from $32.7 million in Q4 2019. R&D expenses decreased to $22.0 million in Q4 2020, while cash and equivalents were $174.8 million as of December 31, 2020, expected to fund operations into mid-2022.
Voyager Therapeutics (NASDAQ: VYGR) will announce its fourth quarter and full year 2020 financial results on February 25, 2021, after market close. A conference call is scheduled for 4:30 p.m. EST to discuss the results and provide a corporate update. Participants can access the call via a designated phone number or through a live webcast on the company's website. Additionally, Voyager will take part in the Cowen 41st Annual Health Care Conference on March 1, 2021 at 11:40 a.m. EST.
Voyager Therapeutics (NASDAQ: VYGR) has entered into an employment agreement providing inducement awards to a new employee. This includes a non-qualified stock option for 76,500 shares and restricted stock units for 13,000 shares. The stock option, effective January 11, 2021, has an exercise price of $8.43 per share. It vests over four years, while the restricted stock units vest annually over three years. These awards were approved by Voyager's Compensation Committee, aligning with Nasdaq regulations. Voyager focuses on gene therapy for severe neurological diseases.
Voyager Therapeutics (Nasdaq: VYGR) announced that the FDA has placed a clinical hold on the RESTORE-1 clinical trial for NBIb-1817 (VY-AADC), an investigational gene therapy for Parkinson's disease. This hold is due to MRI abnormalities observed in some trial participants, and additional patient data is required for review by the Data Safety Monitoring Board (DSMB) in early 2021. The trial had already been inactive due to COVID-19. Voyager and partner Neurocrine Biosciences are working with the FDA to address these concerns and determine the future course of the trial.
Voyager Therapeutics (NASDAQ: VYGR) reported strong third-quarter 2020 results, highlighting significant collaboration revenues of $117.8 million, up from $20.4 million in Q3 2019. The company achieved a net income of $85.6 million, a turnaround from a $15.0 million loss last year. Research and development expenses decreased to $25.0 million from $29.8 million. Despite challenges, including clinical holds and a pause in trial enrollments, Voyager anticipates ending the year with $150-$170 million in cash and equivalents, sufficient for operations into mid-2022.
